Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Calypte’s Receives OK for China HIV Diagnostic Test Facility

publication date: Jan 11, 2008

Calypte Biomedical Corporation (OTCBB: CBMC), a Portland, Oregon company that develops, manufactures and markets HIV diagnostic tests, said its Chinese subsidiary, Beijing Marr Bio-pharmaceutical Co., Ltd., received an SFDA permit to manufacture in vitro diagnostic tests. Calypte is awaiting approval from the SFDA for its rapid oral HIV test. Once approval is secured, Calypte will manufacture the diagnostic test for China and international markets at the Beijing Marr facility. Calypte's Aware™ HIV-1/2 OMT rapid diagnostic test uses oral fluids to diagnose HIV-1 or HIV-2 infection in 20 minutes with high accuracy. More details...

Stock Symbol: (OTCBB: CBMC)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital